Top Page
OrganiGram Holdings
(TSX:OGI)
OrganiGram Holdings (OGI) vs. iShares MSCI Canada ETF (EWC)
OrganiGram Holdings Business Overview & Revenue Model
OrganiGram Holdings Earnings Call Summary
OrganiGram Holdings Financial Statement Overview
| Breakdown | |||||
| TTM | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 194.09M | 159.84M | 149.21M | 145.81M | 79.16M | 86.80M | Gross Profit |
| 63.46M | 47.52M | 35.07M | 31.57M | -28.40M | -56.49M | EBIT |
| -23.65M | -35.67M | -242.74M | -38.75M | -91.82M | -145.51M | EBITDA |
| 7.15M | -23.59M | -207.62M | 12.33M | -95.59M | -121.47M | Net Income Common Stockholders |
| 16.88M | -45.44M | -229.48M | -14.28M | -132.55M | -136.16M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 41.24M | 107.57M | 33.86M | 98.91M | 183.84M | 74.73M | Total Assets |
| 502.28M | 407.86M | 298.45M | 577.11M | 554.02M | 417.62M | Total Debt |
| 86.98M | 4.46M | 4.72M | 3.36M | 4.96M | 103.67M | Net Debt |
| 45.89M | -102.29M | -29.14M | -65.16M | -50.40M | 79.07M | Total Liabilities |
| 124.17M | 101.87M | 26.83M | 69.05M | 74.21M | 118.10M | Stockholders Equity |
| 378.10M | 305.99M | 271.62M | 508.06M | 479.81M | 299.53M |
| Cash Flow | Free Cash Flow | ||||
| -26.74M | -1.47M | -62.70M | -84.99M | -40.92M | -123.78M | Operating Cash Flow |
| -15.60M | 3.87M | -35.80M | -36.21M | -28.59M | -45.13M | Investing Cash Flow |
| -110.36M | -38.77M | 1.35M | 44.03M | -115.11M | -138.20M | Financing Cash Flow |
| 107.52M | 107.78M | -817.00K | 5.33M | 174.46M | 160.37M |
OrganiGram Holdings Technical Analysis
OrganiGram Holdings Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $248.35M | 18.25 | 4.76% | ― | 26.93% | ― | |
54 Neutral | $5.31B | 3.26 | -45.10% | 2.79% | 16.76% | 0.02% | |
| $349.87M | ― | -122.10% | ― | ― | ― | ||
| $312.62M | 36.93 | 4.78% | ― | ― | ― | ||
| $766.26M | 15.51 | 4.61% | ― | ― | ― | ||
| $675.31M | ― | -25.08% | ― | ― | ― | ||
| $754.19M | ― | -12.39% | ― | ― | ― |
OrganiGram Holdings Corporate Events
Organigram Global Inc. announced the retirement of CEO Beena Goldenberg at the end of the fiscal year, with a comprehensive search for a successor underway. Under Goldenberg’s leadership, Organigram grew significantly, becoming Canada’s market leader in cannabis with substantial revenue growth and international expansion. The company is well-positioned for future growth, with the Board expressing confidence in its strategic direction and leadership team.
The most recent analyst rating on (TSE:OGI) stock is a Buy with a C$3.00 price target. To see the full list of analyst forecasts on OrganiGram Holdings stock, see the TSE:OGI Stock Forecast page.
Organigram Holdings reported record financial results for the second quarter of fiscal 2025, with gross revenue reaching $102.8 million and net revenue at $65.6 million, marking significant growth from the previous year. The company’s acquisition of Motif Labs has contributed to increased revenue and is expected to provide $15 million in annual cost synergies. Organigram’s strategic expansion into international markets and the U.S. hemp-derived beverage space, along with its strong market position in Canada, indicates a promising trajectory for future growth.
Organigram Global Inc.’s recently acquired brand, Collective Project, has achieved significant recognition at the 2025 High Spirits Awards in California, winning a gold medal for its Blood Orange, Yuzu & Vanilla beverage and a platinum medal for its Mango, Pineapple & Coconut beverage. These accolades highlight the brand’s rapid success in the U.S. market and reinforce Organigram’s strategy to expand in the cannabis beverage industry, indicating a strong consumer connection and innovative product offerings. The Collective Project’s availability across several U.S. states and upcoming eCommerce platform further support its growth trajectory.
Organigram Global Inc. has been awarded ‘Exporter of the Year’ at the 2025 New Brunswick Export Awards, recognizing its exceptional growth in international cannabis exports, driven by innovation and strategic market expansion. The company has made significant investments in New Brunswick, employing over 725 people and contributing to the local economy. This accolade underscores Organigram’s commitment to enhancing Canada’s position in the global cannabis market and its potential to capture a substantial share of the estimated $140 billion global cannabis industry.
Organigram Global Inc. announced it will release its second quarter fiscal 2025 earnings results on May 12, 2025. The company will host a conference call to discuss these results, with a webcast replay available for 90 days. This announcement is significant as it provides insights into Organigram’s financial performance and strategic positioning within the competitive cannabis market.
Organigram Global Inc., Canada’s leading cannabis company, congratulates Prime Minister Mark Carney on his election win and urges the new government to recognize the cannabis sector as a key component of Canada’s economic growth strategy. The company calls for reforms in taxation, elimination of interprovincial trade barriers, and the development of a national cannabis export strategy to enhance the sector’s financial viability and competitiveness against the illicit market. Organigram highlights the significant economic contributions of the legal cannabis industry, which has added over $43 billion to Canada’s GDP and supports more than 80,000 jobs, advocating for government support to unlock the sector’s full potential.
Organigram Global Inc., a leading Canadian cannabis company, announced that its brands SHRED, Edison, and Trailblazer received accolades at the CNB Leadership Conference and Cannabis NB Cup. SHRED was recognized for its exceptional in-store branding, Edison Sonics Kiwi Berry was awarded Best New Edible, and Trailblazer’s Gary Dunk 3.5g earned third place in the Indica category. These awards highlight Organigram’s strong market presence and commitment to innovation and consumer satisfaction, contributing to its continued growth and leadership in the Canadian recreational cannabis market.
Organigram Global Inc. has released the recording of its OG Investor Session, which includes presentations from senior leadership, facility tours, and a Q&A session. The session highlights Organigram’s strategic initiatives, such as strengthening its position in branded cannabis products, leveraging science for innovation, and expanding international sales. This event serves as a resource for stakeholders to gain insights into the company’s performance and future strategies.
Organigram Global Inc. released a survey revealing strong Canadian support for the legal cannabis industry as a key economic pillar amid global trade tensions. The survey indicates a national desire for economic renewal through homegrown industries, with cannabis seen as a significant contributor to GDP and job creation. The data suggests Canadians expect political leadership to support the cannabis sector, viewing it as an under-leveraged advantage for economic resilience and innovation.
Organigram Global Inc. announced its inaugural virtual investor event, the OG Investor Session, scheduled for April 10, 2025. This event aims to provide investors with insights into the company’s growth strategy and innovation, featuring presentations from key executives. Additionally, the company has officially changed its name on the TSX and NASDAQ to ‘Organigram Global Inc.’ and will continue trading under the symbol ‘OGI’. This rebranding reflects Organigram’s commitment to innovation and market leadership in the cannabis industry.
Organigram has acquired Collective Project Limited, marking its entry into the U.S. hemp-derived THC beverage market and the Canadian cannabis beverage sector. This strategic acquisition allows Organigram to leverage Collective Arts’ brand strength and infrastructure, positioning itself to capitalize on the growing demand for alternative beverages as consumers shift away from alcohol. The move is expected to enhance Organigram’s market presence and revenue potential in both countries.